Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Sunitinib

Catalog No. T0374LCas No. 557795-19-4
Alias SU 11248

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.

Sunitinib

Sunitinib

Purity: 99.67%
Catalog No. T0374LAlias SU 11248Cas No. 557795-19-4
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.
Pack SizePriceAvailabilityQuantity
100 mg$53In Stock
200 mg$81In Stock
500 mg$96In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Sunitinib"

Select Batch
Purity:99.67%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.
Targets&IC50
PDGFRβ:2 nM, VEGFR2:80 nM
In vitro
METHODS: FLT3-ITD cell line MV4;11 and FLT3-WT cell line OC1-AML5 were treated with Sunitinib (0.001-10 µM) for 48 h, and cell viability was assayed using Alamar blue assay.
RESULTS: Sunitinib significantly inhibited the proliferation of MV4;11 and OC1-AML5 cells in a dose-dependent manner, with IC50s of 8 nM and 14 nM, respectively. [1]
METHODS: GIST-T1 gastrointestinal mesenchymal stromal tumor cells were treated with Sunitinib (10-40 nM) for 48 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Sunitinib inhibited the autophosphorylation of c-KIT in a dose-dependent manner, and effectively blocked the phosphorylation of the downstream effectors of c-KIT, Akt and ERK, without affecting the phosphorylated forms of STAT3 and STAT5. [2]
In vivo
METHODS: To assay antitumor activity in vivo, Sunitinib (1-40 mg/kg in a citrate-buffered solution (pH 3.5)) was administered by gavage to athymic nu/nu mice harboring human leukemia tumors MV4;11 once a day until the tumors regressed.
RESULTS: Sunitinib demonstrated dose-dependent efficacy when administered at 4 0 and 20 mg/kg/d and regressed established large subcutaneous tumors. [1]
METHODS: To assay antitumor activity in vivo, Sunitinib (40-80 mg/kg in CMC) was administered by gavage to athymic nu/nu mice injected with breast cancer cells MDA-MB-435/HAL once a day for twenty-one days.
RESULTS: Sunitinib treatment of hormonal mice resulted in a significant reduction in serum PYD levels, confirming the in vivo inhibitory effect of osteolysis. Using BLI, Sunitinib showed 64% inhibition of bone tumor growth at 40 mg/kg/day for 21 days of treatment and 89% inhibition at 80 mg/kg/day. [3]
Kinase Assay
Biochemical Tyrosine Kinase Assays: IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferase fusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST.The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research
Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3. (Only for Reference)
AliasSU 11248
Chemical Properties
Molecular Weight398.47
FormulaC22H27FN4O2
Cas No.557795-19-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 25 mg/mL (62.74 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.25 mg/mL (3.14 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
Solution Preparation Table
10% DMSO+40% PEG300+5% Tween 80+45% Saline/DMSO
1mg5mg10mg50mg
1 mM2.5096 mL12.5480 mL25.0960 mL125.4800 mL
DMSO
1mg5mg10mg50mg
5 mM0.5019 mL2.5096 mL5.0192 mL25.0960 mL
10 mM0.2510 mL1.2548 mL2.5096 mL12.5480 mL
20 mM0.1255 mL0.6274 mL1.2548 mL6.2740 mL
50 mM0.0502 mL0.2510 mL0.5019 mL2.5096 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Sunitinib | purchase Sunitinib | Sunitinib cost | order Sunitinib | Sunitinib chemical structure | Sunitinib in vivo | Sunitinib in vitro | Sunitinib formula | Sunitinib molecular weight